Rearch&DevelopmentCXCR4/CXCL12 Axis
CXCR4 is the only functional chemokine receptor expressed on hematopoietic stem cells (HSC)
CXCL12 promotes:
CXCR4+ cell motility, stimulating cytoskeletal rearrangements (leading edge formation)
CXCR4+ cell homing to CXCL12-rich tissue by upregulating integrins and matrix metalloproteinases(MMPs)
CXCR4 / CXCL12 axis promotes tumor cell proliferation, angiogenesis, and evades the monitoring of the immune system for diffusion.
CXCR4 overexpression has been detected in > 48 cancer types.
PipelineR & D pipeline
JunRui Biotechnology has developed a series of small molecule antagonists targeting CXCR4 / CXCL12 signal axis as novel therapies against cancer. The leading compounds have shown superior in vivo efficacy resulted from better PK and ADME properties. Junrui Biotechnology will pursue more vibrant R & D programs in the future through internal discovery and external collaborations.
Research Collaboration
Junrui Biotechnology collaborates with highly experienced x-function research teams at Medicilon, Crown Bio, Sandia and other CRO companies to achieve R&D outcome.
君睿生物-杭州君睿生物醫藥科技有限公司
新型抗腫瘤小分子藥物的研究和開發
Junrui- Striving to meet the unmet anti-cancer medical needs
Established in 2019, Junrui Biotechnology is striving to meet the unmet anti-cancer medical needs by developing novel small molecule therapies. Located in the Greater Bay Area in Hangzhou, Junrui Biotechnology was founded by a group of experienced researchers used to work in big pharma in USA and is currently focusing on discovery and development of a series small molecule anticancer agents as novel immunomodulatory therapies surrounding CXCR4/CXCL12 signaling axis. This orally available new series of compounds have shown extraordinarily superior in vivo efficacy as compared to other agents targeting the same signaling axis owing to their much improved PK profile and ADME properties. Junrui is partnering with collaborators toward delivering a full IND package in 2021.
Elite Team-Versatile pipeline and novel anticancer therapies
Under the direction of reknowned medicinal chemist with proven track record, Junrui Biotechnology is going to continuously enrich R&D pipelines and explore novel anticancer therapies with better patient benefit. The current discovery surrounding CXCR4/CXCL12 signaling axis will open another chapter of more best-in-class and/or first-in-class drug discoveries in the future.